The earnings call highlighted significant revenue growth, expansion in type 2 non-insulin coverage, and international successes. However, challenges such as gross margin decline and inventory management were noted. Overall, the highlights indicate a strong positive trajectory for DexCom.

Company Guidance -

Q3 2025

During the DexCom Second Quarter 2025 Earnings Call, the company provided optimistic guidance for the remainder of the year, raising its revenue expectations to a range of $4.6 billion to $4.625 billion, representing an annual growth of 14% to 15%. The company reported a 15% organic revenue growth for the quarter, with U.S. revenue totaling $841 million, up 15% year-over-year, and international revenue increasing by 16% to $316 million. Gross profit margin was slightly lower at 60.1% due to continued investments in expedited shipping to stabilize the supply chain, with the expectation to reach a non-GAAP gross margin of approximately 62% by year-end. Operating income increased to $221.8 million, while adjusted EBITDA margin remained robust at 28.3%. With $2.9 billion in cash and equivalents, DexCom is well-positioned to capitalize on strategic opportunities, including increased coverage for type 2 non-insulin users and the upcoming launch of its 15-day G7 System.

Strong Revenue Growth

DexCom reported worldwide revenue of $1.16 billion for Q2 2025, a 15% increase from $1 billion in Q2 2024.

Expansion of Type 2 Non-Insulin Coverage

DexCom secured reimbursement for nearly 6 million type 2 non-insulin lives in the U.S., with coverage now from the three largest commercial PBMs.

Increased Interest in Stelo

The Stelo app has been downloaded more than 400,000 times, indicating growing brand awareness and consumer interest in health wearables.

15-day G7 System Launch

FDA clearance was secured for the 15-day G7 System, with launch planned for the second half of the year.

International Growth and New Coverage

DexCom reported a 16% increase in international revenue and secured new coverage in Ontario, Canada, covering all insulin users.

Positive Clinical Evidence

DexCom presented nearly 40 studies at the ADA's 85th Scientific Sessions, showing significant outcomes for gestational diabetes and type 2 non-insulin care.

Dexcom (DXCM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DXCM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	0.57 / -	0.45	―	―	―
Jul 30, 2025	2025 (Q2)	0.44 / 0.48	0.43	11.63% (+0.05)
May 01, 2025	2025 (Q1)	0.33 / 0.32	0.32	0.00% (0.00)
Feb 13, 2025	2024 (Q4)	0.48 / 0.45	0.5	-10.00% (-0.05)
Oct 24, 2024	2024 (Q3)	0.43 / 0.45	0.5	-10.00% (-0.05)
Jul 25, 2024	2024 (Q2)	0.39 / 0.43	0.34	26.47% (+0.09)
Apr 25, 2024	2024 (Q1)	0.27 / 0.32	0.17	88.24% (+0.15)
Feb 08, 2024	2023 (Q4)	0.43 / 0.50	0.34	47.06% (+0.16)
Oct 26, 2023	2023 (Q3)	0.34 / 0.50	0.28	78.57% (+0.22)
Jul 27, 2023	2023 (Q2)	0.23 / 0.34	0.17	100.00% (+0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DXCM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$89.06	$80.77	-9.31%
May 01, 2025	$70.26	$81.62	+16.17%
Feb 13, 2025	$84.09	$89.07	+5.92%
Oct 24, 2024	$74.85	$73.44	-1.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.